Exact Sciences (EXAS)’s Insider Graham Lidgard Unloaded 35,025 Shares; Last Week Abeona Therapeutics Inc. (ABEO) Coverage

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 36 analyst reports since December 16, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, January 29 by Cantor Fitzgerald. The stock has “Buy” rating by Jefferies on Thursday, June 1. The rating was maintained by H.C. Wainwright on Monday, October 9 with “Buy”. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by RBC Capital Markets on Tuesday, January 23. The firm has “Buy” rating given on Friday, September 8 by H.C. Wainwright. Maxim Group maintained the stock with “Buy” rating in Thursday, September 29 report. As per Thursday, February 1, the company rating was maintained by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 22. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by Maxim Group on Wednesday, August 16. The rating was initiated by Maxim Group with “Buy” on Wednesday, December 16. See Abeona Therapeutics Inc. (NASDAQ:ABEO) latest ratings:

08/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
07/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $34.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
29/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $34.0 Maintain
23/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $26.0 Maintain
04/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
21/11/2017 Broker: Jefferies Rating: Buy New Target: $28.0 Maintain
08/11/2017 Broker: SunTrust Rating: Buy New Target: $26 Initiates Coverage On
02/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $23.0 Maintain

After the publishing of a legal report filled with U.S. Security and Exchange Commission; a sizable and telling insider sale became apparent. The Chief Science Officer of Exact Sciences Corp, Graham Lidgard; executed a huge transaction in the open market by unloading 35,025 shares at an average cost of $42.9 of the public company having an approx. value of $1,501,960 U.S Dollars. Graham is trying to decrease his company’s share, same as he did in the last 30 days. He unloaded another 27,428 shares worth $1,109,266 USD. This big deal is sure to get stock market investors talking about the company. Graham Lidgard now holds 211,148 shares of Exact Sciences Corp.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $647.84 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

The stock decreased 0.72% or $0.1 during the last trading session, reaching $13.85. About 690,516 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 151.02% since March 1, 2017 and is uptrending. It has outperformed by 134.32% the S&P500.

Among 18 analysts covering EXACT Sciences (NASDAQ:EXAS), 9 have Buy rating, 1 Sell and 8 Hold. Therefore 50% are positive. EXACT Sciences has $67.0 highest and $4 lowest target. $42.59’s average target is -4.53% below currents $44.61 stock price. EXACT Sciences had 68 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Neutral” rating given on Thursday, February 25 by Roth Capital. The rating was initiated by BTIG Research with “Buy” on Friday, December 18. The firm earned “Buy” rating on Monday, November 13 by Leerink Swann. The firm earned “Buy” rating on Thursday, February 25 by Jefferies. The stock has “Buy” rating by Jefferies on Friday, October 20. Craig Hallum maintained the shares of EXAS in report on Wednesday, July 26 with “Buy” rating. As per Wednesday, October 26, the company rating was maintained by Benchmark. As per Tuesday, February 21, the company rating was upgraded by Benchmark. As per Wednesday, October 7, the company rating was downgraded by Lake Street. The rating was maintained by TH Capital on Tuesday, October 6 with “Buy”.

Since September 5, 2017, it had 0 insider buys, and 13 selling transactions for $28.63 million activity. 125,402 shares were sold by Conroy Kevin T, worth $6.62 million on Friday, January 12. COWARD D SCOTT sold 29,115 shares worth $1.37M. On Tuesday, September 5 the insider LIDGARD GRAHAM PETER sold $3.09M. 2,982 Exact Sciences Corporation (NASDAQ:EXAS) shares with value of $126,252 were sold by Elliott Jeffrey Thomas. $522,959 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by ARORA MANEESH on Friday, February 23.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $5.40 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

The stock increased 0.54% or $0.24 during the last trading session, reaching $44.61. About 2.23M shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 458.24% since March 1, 2017 and is uptrending. It has outperformed by 441.54% the S&P500.